Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort

• Published in: International journal of hematology 2024-09, Vol.120 (3), p.347-355
• Main Authors: Ohwada, Chikako, Sakaida, Emiko, Takeda, Yusuke, Doki, Noriko, Igarashi, Aiko, Onizuka, Makoto, Toyosaki, Masako, Tanaka, Masatsugu, Tachibana, Takayoshi, Kataoka, Keisuke, Kato, Jun, Fujisawa, Shin, Kato, Seiko, Nakasone, Hideki, Naganuma, Ken, Saitoh, Takayuki, Shono, Katsuhiro, Hagihara, Maki, Saito, Takeshi, Usuki, Kensuke, Mori, Takehiko, Nakaseko, Chiaki, Okamoto, Shinichiro, Kanda, Yoshinobu
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Chronic Disease; East Asian People; Female; Graft vs Host Disease - diagnosis; Graft vs Host Disease - etiology; Graft vs Host Disease - mortality; Graft-versus-host reaction; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Japan - epidemiology; Lungs; Male; Medicine; Medicine & Public Health; Middle Aged; Observational studies; Oncology; Oral cavity; Original Article; Patients; Prospective Studies; Survival; Survival Rate; Time Factors; Treatment Outcome; Young Adult
• ISSN: 0925-5710; 1865-3774; 1865-3774
• DOI: 10.1007/s12185-024-03813-0

A prospective multicenter observational study of organ response was conducted in patients with chronic GVHD diagnosed by the NIH criteria. When response was assessed at 12 months (12 M) in 118 patients, 74.6% were classified as responders and 25.4% as non-responders. The skin and oral cavity were the most frequent organs used as the basis for determining overall response. The lungs, liver, and eyes were also used in 20% of patients. Non-response decisions at 12 M were most frequent in the lungs. A significantly higher percentage of responders than non-responders completed systemic treatment (24.3% vs. 3.3%, P = 0.02). Global scoring showed significant changes, with improvement in responders and worsening in non-responders throughout the observation period. Two-year transplant-related mortality, using the 12 M assessment as the landmark, was significantly worse in non-responders (28.5% vs. 2,7%, P  = 0.0001), while the 2-year recurrence rate was equivalent (5.4% vs. 4.8%, P  = 0.78). Consequently, the 2-year overall survival rate from the 12 M assessment was significantly better in responders than non-responders (95% vs. 65.3%, P  = 0.0001). Our data suggests that patients who do not achieve a response within the first year should be candidates for clinical studies on chronic GVHD.